Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Catecholaminergic Polymorphic Ventricular Tachycardia

Cardiovascular

Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Clinical Trials

Also called CPVT, polymorphic ventricular tachycardia, RYR2 mutation

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited cardiac arrhythmia syndrome characterized by exercise- or catecholamine (epinephrine/adrenaline)-induced bidirectional or polymorphic ventricular tachycardia with high risk of sudden cardiac death. Autosomal dominant CPVT, the most common form, results from mutations in the RYR2 gene encoding cardiac ryanodine receptor (calcium release channel in sarcoplasmic reticulum), while autosomal recessive forms result from CASQ2 mutations encoding calsequestrin-2 (calcium-binding protein).

In plain words, catecholaminergic polymorphic ventricular tachycardia is a genetic heart rhythm problem set off by stress, strong emotion or exercise. Gene changes upset how heart cells handle calcium, which can cause sudden fast heartbeats and fainting.

Get an email when new Catecholaminergic Polymorphic Ventricular Tachycardia trials open or the FDA decides. Get alerts

Catecholaminergic Polymorphic Ventricular Tachycardia

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 2 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Catecholaminergic Polymorphic Ventricular Tachycardia yet.

Catecholaminergic Polymorphic Ventricular Tachycardia has no FDA-approved medicines, 5 open or active clinical trials (5 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Catecholaminergic Polymorphic Ventricular Tachycardia

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Catecholaminergic Polymorphic Ventricular Tachycardia

These mutations impair intracellular calcium handling and cycling, causing abnormal calcium dynamics within myocytes that trigger ectopic activity. Crucially, affected patients have structurally normal hearts and normal baseline ECGs at rest, distinguishing CPVT from other inherited arrhythmia syndromes.

Keep reading about Catecholaminergic Polymorphic Ventricular Tachycardia

Stress, exercise, or strong emotional stimuli trigger bidirectional ventricular tachycardia (alternating axis on ECG) or polymorphic ventricular tachycardia that can rapidly degenerate to ventricular fibrillation and sudden death. Symptoms typically begin in childhood or adolescence with unexplained syncope during exercise or emotional stress, though some patients remain asymptomatic until provoked.

What are the symptoms of Catecholaminergic Polymorphic Ventricular Tachycardia?

These are common symptoms of Catecholaminergic Polymorphic Ventricular Tachycardia, and how strong they are varies from person to person.

  • Syncope triggered by stress, emotion, or exercise
  • Polymorphic or bidirectional ventricular tachycardia
  • Sudden cardiac death risk, especially in children
  • Palpitations and light-headedness
  • Normal baseline ECG
  • Exercise-induced symptoms

Who gets Catecholaminergic Polymorphic Ventricular Tachycardia?

Catecholaminergic polymorphic ventricular tachycardia often manifests in childhood to young adulthood with stress or emotion-triggered syncope, though some patients remain asymptomatic until later years or until cardiac events occur.

The condition affects males and females. RYR2 mutations, inherited in an autosomal dominant pattern, cause about half of all cases, with ~50% of offspring of affected parents inheriting mutations. Autosomal recessive forms (CASQ2 mutations) are found primarily in certain populations including Middle Eastern and Mediterranean ancestry groups. De novo mutations account for minority of cases.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new Catecholaminergic Polymorphic Ventricular Tachycardia medicines are in trials?

Investigational medicines Trial Friend tracks for Catecholaminergic Polymorphic Ventricular Tachycardia, with trial results, safety findings and where each one stands.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Catecholaminergic Polymorphic Ventricular Tachycardia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Catecholaminergic Polymorphic Ventricular Tachycardia resources

Reputable organizations and medical references for learning more about Catecholaminergic Polymorphic Ventricular Tachycardia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Catecholaminergic Polymorphic Ventricular Tachycardia

Use this Catecholaminergic Polymorphic Ventricular Tachycardia clinical trial finder to see the 5 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 3 test a treatment and 2 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

5 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 1Recently updatedNCT07148089

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Intervention: SGT-501

Sponsor: Solid Biosciences Inc.

This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus o...

Ages 7 Years+
Started Feb 2026Updated 3 weeks agoEst. Jun 2027 (~7 months)
RecruitingTreatment trialPhase 2Updated a few months agoNCT06658899

A Phase 2 Study of CRD-4730 in CPVT

Intervention: CRD-4730, Placebo

Sponsor: Cardurion Pharmaceuticals, Inc.

This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricu...

Ages 18 Years to 99 Years
Started Dec 2025Updated 4 months agoEst. Apr 2027 (~5 months)
RecruitingObservational study, no treatment givenNo updates in a whileNCT06546137

National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry

Intervention: whole genome sequencing

Sponsor: Hospital do Coracao

The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:

Ages not specified
Started Apr 2025Updated 6 months agoEst. Aug 2026
RecruitingTreatment trialPhase 2No updates in a whileNCT07263139

Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Intervention: AGP100

Sponsor: Agiana Pharmaceuticals · Link Medical Research AB

This trial is conducted in patients with an inherited heart rhythm disorder called catecholaminergic polymorphic ventricular tachycardia (CPVT). This condition causes the heart to beat dangerously fast during situations of physical or emotional stress. CPVT is a serious condition...

Ages 18 Years to 75 Years1 location
Expected to start Jan 2026Updated 10 months agoEst. Jun 2027 (~7 months)
RecruitingObservational study, no treatment givenHasn't posted an update in over a yearNCT05521451

Clinical Cohort Study - TRUST

Sponsor: Universitätsklinikum Hamburg-Eppendorf

The "Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac ...

Ages 18 Years+1 location
Started Mar 2021Updated 1 year agoEst. Sep 2026
Find Catecholaminergic Polymorphic Ventricular Tachycardia trials near you, ranked by distance →
Active trial locations9 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+1 more

Trial Pipeline

Mar 2021 to Nov 2031
2022
2024
2026
2028
2030
now
Phase 1
Phase 2
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Catecholaminergic Polymorphic Ventricular Tachycardia trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Catecholaminergic Polymorphic Ventricular Tachycardia foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Catecholaminergic Polymorphic Ventricular Tachycardia patient communities

Facebook groups, Reddit communities and YouTube channels where Catecholaminergic Polymorphic Ventricular Tachycardia patients, caregivers and advocacy groups talk.

Companies developing Catecholaminergic Polymorphic Ventricular Tachycardia treatments

Drugmakers that list Catecholaminergic Polymorphic Ventricular Tachycardia in their rare disease portfolio, 1 in all.

Questions people ask about Catecholaminergic Polymorphic Ventricular Tachycardia